Clinical testing for hereditary cancer coming 2026
TransCan Genomics is partnering with Canadian clinical laboratories to provide a domestic option for hereditary cancer testing. Launching Q2 2026, we’re committed to supporting Canada’s genomic data sovereignty and repatriating genetic testing.
Get notified
Sign up below to be notified when provider registration is open and receive updates on our products and services.
Interested in joining in our pre-launch program? Register for our Early Access Program and be first to access our WGS-based clinical hereditary cancer panel. Learn more →